F S&P 500
5,124.75 +42.50 (+0.84%) F Dow Jones
38,332.00 +44.00 (+0.11%) F Nasdaq
17,776.25 +208.75 (+1.19%) E-mini Russell 2000 Index Futur
1,989.10 -4.10 (-0.21%) Petróleo
83.82 +0.25 (+0.30%) Oro
2,345.20 +2.70 (+0.12%)
Oncopeptides AB (publ) (ONCO.ST)
Oncopeptides AB (publ)
Vastra Tradgardsgatan 15
Stockholm 111 53
Sweden
46 86 15 20 40
https://www.oncopeptides.com/sv
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 57
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer | 7.26M | N/D | 1972 |
| Ms. Sofia Heigis M.Sc. | Chief Executive Officer | N/D | N/D | 1980 |
| Prof. Rolf Larsson M.D., Ph.D. | Founder | N/D | N/D | N/D |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder | N/D | N/D | N/D |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder | N/D | N/D | N/D |
| Dr. Kristina Luthman Ph.D. | Founder | N/D | N/D | N/D |
| Prof. Hans Ehrsson M.D. | Founder | N/D | N/D | N/D |
| Mr. Peter Nygren | Founder | N/D | N/D | 1959 |
| Mr. Henrik Bergentoft | Chief Financial Officer | N/D | N/D | 1974 |
| Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD | N/D | N/D | 1970 |
Descripción
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Gestión corporativa
La calificación ISS Governance QuickScore de Oncopeptides AB (publ) a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
